This may indicate that C/EBPδ-dependent tumor cell extravasation is only partly PAFR-dependent (although sub-optimal targeting by the PAFR antagonist cannot be excluded as a possible explanation for the difference between targeting versus genetic ablation). This evidence concerns the gene CEBPD and neoplasm.